Clinical trials: Diffuse Parenchymal Lung Diseases
Asbestos Exposure
Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population
This is a single-arm phase II trial to assess the biological activity (in a sub-cohort using a Simon two-stage Phase II design) and toxicity of Artichoke Whole Phytocomplex Concentrate (WPC).
- Trial name
- ABOCA1 (NCT02076672)
- Testing
- Artichoke WPC
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Silicosis
Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone)
Silicosis is well-known occupational disease caused by free crystalline silica (silicon dioxide) and is marked by inflammation and pulmonary fibrosis.
- Trial name
- NCT01338064
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Interstitial Lung Disease (ILD), Connective Tissue Disease-associated Interstitial Lung Disease
A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease
This study evaluates the efficacy and safety of tetrandrine tablets (60 mg, three times daily) compared to placebo in adult patients with connective tissue disease-related interstitial lung disease.
- Trial name
- NCT07319598
- Testing
- Tetrandrine Tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Langerhans Cell Histiocytosis
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral…
- Trial name
- NCT00588536
- Testing
- Methotrexate, 6-Thioguanine, Leucovorin Calcium
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pulmonary Healthy Controls, Interstitial Lung Disease
Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Current diagnostic tools used in interstitial lung disease (ILD) do not meet the challenges set by the complex pathophysiology of this heterogenous group.
- Conditions
- Pulmonary Healthy Controls, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Non-specific Interstitial Pneumonia
- Trial name
- NCT02827734
- Testing
- multiple breath washout tests, impulse oscillometry, body plethysmography
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universitätsmedizin Mannheim
Idiopathic Pulmonary Fibrosis
Changes in iOS in IPF
Idiopathic pulmonary fibrosis (IPF) is a condition where scar tissue (called fibrosis) builds up in the lungs. It usually gets worse over time.
- Trial name
- NCT04572958
- Where
- United Kingdom
- Volunteers
- 132 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cardiovascular Disease, Asthma
Effectiveness of Pollution Monitoring in Clinical Exercise Rehabilitation
The primary objective of EPIC-AIR is to evaluate the feasibility and potential effectiveness of integrating real-time air pollution monitoring into cardiac rehabilitation (CR) and pulmonary rehabilitation (PR) programmes via an…
- Conditions
- Cardiovascular Disease, Asthma, COPD, Interstitial Lung Disease Due to Systemic Disease
- Trial name
- EPIC-AIR (NCT07500948)
- Testing
- Progressive Walking Exercise Programme, Real-time air quality information and guidance
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Interstitial Lung Disease
Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies
Diffuse interstitial lung diseases (ILDs) represent a group of rare, heterogeneous disorders of various etiologies, all sharing a common histopathological feature: fibrotic remodeling of the pulmonary parenchyma induced by a…
- Trial name
- INTREPID (NCT06980844)
- Testing
- No intervention: no treatment
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hopital Foch
Interstitial Lung Diseases
Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology
Nanoparticles (NP) are particles whose length, width and height are less than 100 nanometres. Over the past decade, industrial applications of NP have increased dramatically.
- Trial name
- NANOPI (NCT02549248)
- Testing
- BAL, BW, EAC
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Community-Acquired Bacterial Pneumonia (CABP)
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).
- Trial name
- NCT01198626
- Testing
- JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 32 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Recurrent Ependymoma, Recurrent Ewing Sarcoma
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors, including central nervous system tumors, lymphomas and histiocytic disorders that have not responded to (refractory) or…
- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis
- Trial name
- NCT04195555
- Testing
- Ivosidenib
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Transbronchial Cryobiopsy, Freezing Time
The Diagnostic Yield and Safety of Transbronchial Cryobiopsy in Different Freezing Time in the Diffuse Parenchymal Lung Diseases
Transbronchial cryobiopsy in different freezing time is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
- Conditions
- Transbronchial Cryobiopsy, Freezing Time, Diagnostic Yield, Safety
- Trial name
- NCT03927235
- Testing
- Transbronchial Cryobiopsy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Lung Diseases, Interstitial
Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcomes among patients with…
- Trial name
- NCT05957198
- Where
- United States
- Volunteers
- 114,921 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer, Stage III NSCLC
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC
Previous clinical studies showed there is a potential value of EGFR-TKI in local advanced EGFR-mutant NSCLC, while the risk of radiation pneumonia in combination of EGFR-TKI with thoracic radiotherapy is unknown.
- Conditions
- Non Small Cell Lung Cancer, Stage III NSCLC, EGFR Activating Mutation
- Trial name
- NCT04636593
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 43 people
- Sponsor
- First People's Hospital of Hangzhou
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasm
- Trial name
- PICSI-H (NCT04281784)
- Testing
- EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 2,512 people
- Sponsor
- University of Washington
Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
The purpose of this study is to determine the safety and efficacy of a therapeutic regimen consisting of 4 weeks of glucocorticoids given with a combination of the usual induction agents for ANCA-associated vasculitis.
- Trial name
- SAFE-LOW (NCT06983821)
- Testing
- Cyclophosphamide, Standard of Care (SOC), Prednisone
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Hospital Research Institute
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
PR3-AAV Resilient Remission or PRRR
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
- Trial name
- NCT05376319
- Testing
- Obinutuzumab, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Sarcoidosis, Pulmonary
Acthar Gel in Participants With Pulmonary Sarcoidosis
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a…
- Trial name
- PULSAR (NCT03320070)
- Testing
- Acthar Gel
- Where
- 29 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mallinckrodt
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
Ambrisentan is an endothelin receptor antagonist used for the treatment of pulmonary hypertension (PH). Based on research suggesting a role for endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the poor…
- Trial name
- ARTEMIS-PH (NCT00879229)
- Testing
- Ambrisentan
- Where
- 85 sites in United States, Australia and 5 more
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Pulmonary Hypertension, Interstitial Lung Disease
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with…
- Trial name
- NCT05649722
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 22 sites in Argentina, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Insmed Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.